Blood Pressure: The Moving Target

One in four adults on earth is on blood pressure medication. After the age of sixty-five, that number crosses fifty percent. Antihypertensives are the most prescribed drug class in the world. This did not happen because blood pressure became more dangerous. It happened because the definition of what counts as dangerous blood pressure kept changing — and each change expanded the treatment population by tens of millions of people.

What Doctors Once Believed — and Why

Until the mid-twentieth century, elevated blood pressure in older adults was not viewed as a disease. It was viewed as physiology. Ageing arteries stiffen, lose elasticity, and require more driving pressure to deliver adequate blood flow to the brain, kidneys, and heart. The body compensates by raising the pressure. Clinicians worked with this, not against it.

The working rule was simple: systolic pressure = 100 plus age. A 65-year-old man with a reading of 165 was within normal range. A 70-year-old woman at 170 was unremarkable. The term for primary high blood pressure — essential hypertension — carried its original meaning: the elevated pressure was considered essential to organ perfusion in an ageing vascular system. Physicians who attempted to lower it were warned they risked starving the brain and kidneys of oxygen.

This was not mere ignorance. It had anatomical logic. And it had a famous casualty that clarified where the logic broke down.

The Framingham Foundation — and What It Did Not Say

The shift from clinical tolerance to systematic treatment was driven by epidemiology. The Framingham Heart Study, launched in 1948 in Framingham, Massachusetts, was the first large-scale longitudinal cardiovascular study. It followed 5,209 residents over decades and identified what it called "risk factors" — variables associated with cardiovascular events over time. Blood pressure was among them. The higher the recorded pressure, the greater the statistical risk of heart attack and stroke in the cohort over the following years.

This finding was real. The association between extreme hypertension and cardiovascular events is biologically plausible and confirmed across multiple populations. FDR at 300/190 is not ambiguous.

But the study had structural limitations that were acknowledged by its own investigators — and findings that were suppressed by its primary funder.

The more fundamental problem was not the study's design — it was how its findings were applied. Framingham was observational: people with naturally lower blood pressure tended to have better cardiovascular outcomes. From this, a clinical directive was derived: lower everyone's blood pressure through medication and the outcomes will follow.

This is the same logical error that produced the HRT disaster of the 1990s. Observational data showed women taking hormone replacement therapy had better cardiac outcomes — so HRT was prescribed for cardiovascular protection. The Women's Health Initiative RCT, when eventually conducted, showed HRT raised the risk of heart disease, stroke, and breast cancer. The better outcomes in the observational data were a marker of which women chose HRT — healthier, more educated, higher income — not a consequence of the treatment itself. When you randomise the treatment, the association disappears or reverses.

Blood pressure medicine has not undergone the same reckoning. The observational logic has never been fully stress-tested with the question: does aggressively medicating someone to a lower blood pressure produce the same benefit as naturally having a lower blood pressure?

The Threshold Escalation

From the late 1970s onward, a series of Joint National Committee guidelines progressively refined — and progressively lowered — the definition of hypertension requiring treatment.

The 2017 move from 140/90 to 130/80 raised the prevalence of hypertension in the United States from 32% to 46% of all adults. Not because anyone's blood pressure changed. Because the definition did.

The SPRINT Trial — The Evidence Behind the 2017 Shift

The primary justification for lowering the target to 130/80 was the SPRINT trial, published in the New England Journal of Medicine in November 2015. SPRINT compared intensive blood pressure management (target below 120 mmHg systolic) against standard management (target below 140 mmHg) in adults at high cardiovascular risk. The intensive group showed fewer cardiovascular events and lower all-cause mortality. The trial was stopped early, after a median follow-up of 3.34 years, due to apparent benefit.

A closer examination reveals structural problems that were documented in peer-reviewed literature and acknowledged by critical cardiologists.

The J-Curve: When Lower Becomes Dangerous

The clinicians of the early twentieth century were not entirely wrong in their concern. The relationship between blood pressure and mortality in treated hypertensive patients is not linear. It is J-shaped.

The original intuition — that ageing, stiffened vessels require higher driving pressure to perfuse downstream organs — has anatomical grounding. The aged aorta loses elasticity, cannot buffer the cardiac ejection wave, and the arterial tree requires a higher mean pressure to maintain adequate cerebral and renal blood flow. Aggressive pharmacological reduction of this compensatory pressure in a 75-year-old is not obviously beneficial, and the J-curve data suggest it can be harmful.

None of this is to say that 300/190 should be left untreated. It should not. The question is where, precisely, the intervention threshold lies — and whether that threshold should be identical for a 40-year-old and a 75-year-old with stiff vessels and baseline orthostatic hypotension. Current guidelines apply a near-universal target that the evidence does not support universally.

What Actually Drives Blood Pressure Up

The conventional framework treats blood pressure as a primary variable to be managed with medication. The terrain framework asks a prior question: why is the pressure elevated in the first place?

Elevated blood pressure is a symptom. In most cases it is a symptom of upstream terrain failure — not a disease in itself. The most common and well-documented physiological drivers:

The Botanical Protocol

These mechanisms have botanical counterparts with peer-reviewed mechanistic documentation. The following are not presented as replacements for emergency antihypertensive treatment in crisis situations — they are terrain-level interventions addressing the upstream drivers that medication does not touch.

The Protocol — Terrain Before Pharmacology

The Sovereign Position

The original question — does blood pressure matter? — has a clear answer: yes, at extremes. Blood pressures above 180/110 carry documented and mechanistically plausible risk. At those levels, intervention is rational.

The modern question is different: does the progressive lowering of intervention thresholds, driven by epidemiological data from a single non-representative cohort and justified by a methodologically flawed trial whose steering committee chair also chaired the guideline panel, represent good medicine?

The J-curve data say no — for the elderly in particular. The AAFP's refusal to endorse the 2017 guidelines says no. The 31 million Americans reclassified as diseased overnight, without any change in their biology, says the mechanism here is familiar.

Acute disease creates patients. Chronic disease creates customers. A threshold set at 140/90 treats a smaller population than one set at 130/80. The pharmacological management of the difference between 135 and 139 mmHg systolic in a 68-year-old with no cardiovascular history does not have robust evidence behind it. The drug that treats it has a patent life and a quarterly earnings report.

Know your number. Understand what drives it. Address the terrain. And ask — every time a guideline changes — who benefits from the revision.